nnc0142-0002
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT00927927)
Timeline
Indications
Mechanism of action
KLRK1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- nnc0142-0002
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01181050 | Phase 2 | Aug 1, 2010 | Johnson and Johnson, Novo Nordisk |
| NCT00927927 | Phase 1 | Jun 1, 2009 | Johnson and Johnson, Novo Nordisk |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 2 | 2 | 2 | 2009 |
| Novo Nordisk | For profit | 2 | 0 | 2 | 2009 |
2 organizations
Page 1 / 1